See more : Jiangsu Expressway Company Limited (600377.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Verici Dx plc (VRCI.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Verici Dx plc, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- ARC Funds Limited (ARC.AX) Income Statement Analysis – Financial Results
- GreenBox POS (GBOX) Income Statement Analysis – Financial Results
- The Hempshire Group, Inc. (HMPSF) Income Statement Analysis – Financial Results
- Consolidated Uranium Inc. (CUR.V) Income Statement Analysis – Financial Results
- Lanzhou Zhuangyuan Pasture Co., Ltd. (1533.HK) Income Statement Analysis – Financial Results
Verici Dx plc (VRCI.L)
About Verici Dx plc
Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Penarth, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 1.01M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.01M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 4.83M | 2.81M | 0.00 |
| General & Administrative | 8.60M | 10.50M | 2.56M | 2.10M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.60M | 10.50M | 2.56M | 2.10M |
| Other Expenses | 1.28M | 958.00K | 3.14M | 0.00 |
| Operating Expenses | 9.88M | 11.46M | 8.51M | 7.00M |
| Cost & Expenses | 9.88M | 11.46M | 8.51M | 7.00M |
| Interest Income | 162.00K | 53.00K | 0.00 | 0.00 |
| Interest Expense | 29.00K | 5.00K | 0.00 | 104.57K |
| Depreciation & Amortization | 829.00K | 640.00K | 438.00K | 288.35K |
| EBITDA | -7.59M | -10.50M | -7.15M | -2.10M |
| EBITDA Ratio | -748.77% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.87M | -11.46M | -8.33M | -2.39M |
| Operating Income Ratio | -875.32% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 133.00K | 48.00K | -829.00 | -4.71M |
| Income Before Tax | -8.73M | -11.41M | -8.33M | -7.10M |
| Income Before Tax Ratio | -862.19% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -48.00K | -740.00K | 0.00 |
| Net Income | -8.73M | -11.36M | -8.33M | -7.10M |
| Net Income Ratio | -862.19% | 0.00% | 0.00% | 0.00% |
| EPS | -0.05 | -0.07 | -0.06 | -0.08 |
| EPS Diluted | -0.05 | -0.07 | -0.06 | -0.08 |
| Weighted Avg Shares Out | 170.32M | 164.67M | 141.75M | 86.73M |
| Weighted Avg Shares Out (Dil) | 170.32M | 164.67M | 141.75M | 86.73M |
Source: https://incomestatements.info
Category: Stock Reports